PT  - JOURNAL ARTICLE
AU  - Schumacher, Jackson G.
AU  - Zhang, Xinyuan
AU  - Wang, Jian
AU  - Bayati, Armin
AU  - Dijkstra, Johannes M.
AU  - Watanabe, Hirohisa
AU  - Schwarzschild, Michael A.
AU  - Cortese, Marianna
AU  - Zhang, Xuehong
AU  - Chen, Xiqun
TI  - α-Synuclein seeding activity and progression in sporadic and genetic forms of Parkinson’s disease in the Parkinson’s Progression Markers Initiative cohort
AID  - 10.1101/2024.09.27.24311107
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.27.24311107
4099  - http://medrxiv.org/content/early/2024/09/30/2024.09.27.24311107.short
4100  - http://medrxiv.org/content/early/2024/09/30/2024.09.27.24311107.full
AB  - Background α-Synuclein (α-syn) seed amplification assays (SAAs) have shown remarkable potential as a diagnostic tool for Parkinson’s disease (PD). Using data from the Parkinson’s Progression Markers Initiative (PPMI) cohort, we aimed to assess whether baseline α-syn seeding and seed concentration are associated with progression in sporadic PD, LRRK2-associated PD (LRRK2 PD), and GBA-associated PD (GBA PD).Methods Using a linear mixed-effects model adjusted for potential confounding factors, we analyzed 14 years of motor and cognitive assessments and five years of dopamine transporter imaging data from 878 PPMI participants to establish comprehensive progression profiles for sporadic PD (n=473), LRRK2 PD (n=275), and GBA PD (n=130). By introducing α-syn SAA results from 586 participants (n=351 sporadic PD, 163 LRRK2 PD, and 72 GBA PD), we determined whether baseline α-syn seeding positivity (95% sporadic PD, 69% LRRK2 PD, and 94% GBA PD) and the time to 50% of the maximum fluorescence (T50), an indicator of seed concentration, are associated with progression in PD.Findings Participants with sporadic PD (yearly change in MDS-UPDRS III: 1.50 points; 95% confidence interval 1.41–1.58) and GBA PD (1.52; 1.31–1.72)(p=0.873) progressed similarly while those with LRRK2 PD progressed slower (1.05; 0.89–1.20)(p<0.001). There was no significant difference between α-syn SAA+ sporadic PD (1.48; 1.03–1.92) and LRRK2 PD (1.09; 0.76–1.44) participants and their negative counterparts (1.25; 0.81–1.70)(p=0.347)(0.80; 0.50–1.10)(P=0.087). Similarly, α-syn seeding activity was not significantly associated with progression in GBA PD. Furthermore, there was no statistically significant difference in progression between sporadic PD participants with high (1.46; 1.33–1.59), medium (1.45; 1.30–1.61)(p=0.948), and low seed concentration (1.42; 1.11–1.73)(p=0.804). Similarly, seed concentration was not significantly associated with progression in LRRK2 or GBA PD.Interpretation Baseline α-syn seeding activity and seed concentration were not statistically significantly associated with PD progression in the PPMI cohort. More longitudinal investigations into the relationship between α-syn seeding activity, seed concentration, and progression are needed before concretely establishing α-syn aggregation as the primary driver of PD.Funding This study was funded in part by Aligning Science Across Parkinson’s No. ASAP-237603 through the Michael J. Fox Foundation for Parkinson’s Research and the National Institute of Health through the National Institute of Neurological Disorders and Stroke grant R01NS102735.Competing Interest StatementJGS, XYZ, JW, AB, JD, MAS, MC, XHZ, and XC declare no conflicts of interest. HW received payments from Takeda Pharmaceuticals, AbbVie, Kyowa Kirin, Sumitomo Pharma, Eisai, and Ono Corporation for work unrelated to this study.Funding StatementThis research was funded in part by Aligning Science Across Parkinson's No. ASAP-237603 through the Michael J. Fox Foundation for Parkinson's Research (MJFF) and by the National Institute of Health through the National Institute of Neurological Disorders and Stroke grants R01NS102735 and 5R01NS126260. These funders had no role in study design, analysis, interpretation of data, in the writing of the report, and/or in the decision to submit the paper for publication. The authors would like to thank PPMI, a public-private partnership, funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in the preparation of this article is openly available and was obtained in May 2024 from the Parkinson's Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/access-dataspecimens/download-data), RRID: SCR006431.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in the preparation of this article is openly available, and in the case of whole genome sequencing data, it is available upon request. Data was obtained in June 2024 from the Parkinson's Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/access-dataspecimens/download-data), RRID: SCR006431. For up-to-date information on the study, visit www.ppmi-info.org. All other resources used in this study can be found at doi:10.5281/zenodo.13852003. For the purpose of open access, the author has applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission. https://www.ppmi-info.org/access-dataspecimens/download-data https://www.ppmi-info.org https://doi.org/10.5281/zenodo.13852003